In terms of therapeutic potential, it has been shown that silencing ANXA2 using shRNA effectively reduces hepatoma cell invasion, migration, and tumorigenicity (Zhang H. J. et al., 2013; Dong et al., 2014). Here, ANXA2 is linked to hepatocellular carcinoma.